PIZENSY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PIZENSY (PIZENSY).
Selective sodium-glucose cotransporter 2 (SGLT2) inhibitor; reduces renal glucose reabsorption, lowering blood glucose.
| Metabolism | Primarily metabolized via glucuronidation by UGT1A9 and UGT2B7; minimal CYP involvement. |
| Excretion | PIZENSY (pirenzepine) is primarily excreted unchanged in urine, with 80-90% of the administered dose eliminated via renal excretion. The remainder is eliminated via biliary/fecal routes (10-20%). |
| Half-life | The terminal elimination half-life is approximately 10-12 hours. This half-life supports twice-daily dosing for sustained anticholinergic effect in peptic ulcer therapy. |
| Protein binding | Approximately 10-15% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Volume of distribution is approximately 0.5-0.7 L/kg, indicating distribution into total body water and moderate tissue binding. |
| Bioavailability | Oral bioavailability is approximately 20-30% due to extensive first-pass metabolism. |
| Onset of Action | Oral administration: Onset of antisecretory effect occurs within 1-2 hours. Intravenous administration: Onset within 15-30 minutes. |
| Duration of Action | Duration of antisecretory effect is 8-12 hours after oral administration, supporting twice-daily dosing. Clinical effect on gastric acid secretion persists for the dosing interval. |
1.6 mg orally twice daily (morning and late afternoon, at least 4-6 hours before bedtime). Titrate weekly based on tolerability.
| Dosage form | SOLUTION |
| Renal impairment | No adjustment required for mild-to-moderate renal impairment. For severe renal impairment (eGFR <30 mL/min), use 1.6 mg once daily in the morning. |
| Liver impairment | Child-Pugh A or B: No adjustment. Child-Pugh C: Use 1.6 mg once daily in the morning. |
| Pediatric use | Not recommended for patients under 18 years of age; safety and efficacy not established. |
| Geriatric use | Start with 1.6 mg once daily in the morning; titrate cautiously due to increased risk of dizziness and falls. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PIZENSY (PIZENSY).
| Breastfeeding | Pegvaliase is a large protein (approximately 600 kDa) and likely excreted into breast milk in minimal amounts, but no data exist. M/P ratio unknown. Due to potential for gastrointestinal degradation in the infant, oral bioavailability is expected to be low. Consider developmental and health benefits of breastfeeding alongside mother's need for therapy. |
| Teratogenic Risk | PIZENSY (pegvaliase) is a recombinant phenylalanine ammonia lyase. In animal reproduction studies, no adverse developmental effects were observed in pregnant rabbits or rats at exposures up to 10 times the human systemic exposure. However, pegvaliase causes maternal phenylalanine reduction, which may indirectly benefit fetal development by lowering maternal phenylalanine levels. There are no adequate human data. Risk cannot be ruled out; use only if benefit outweighs risk. First trimester: theoretical risk of phenylalanine deficiency affecting organogenesis. Second and third trimesters: maternal phenylalanine control may reduce risk of fetal neurodevelopmental deficits associated with hyperphenylalaninemia. |
■ FDA Black Box Warning
None.
| Serious Effects |
Severe renal impairment (eGFR <30 mL/min/1.73 m2), end-stage renal disease or dialysis, history of serious hypersensitivity to canagliflozin.
| Precautions | Risk of diabetic ketoacidosis, acute kidney injury, urosepsis and pyelonephritis, lower limb amputation, genital mycotic infections, volume depletion, hypotension. |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum phenylalanine levels every 2 weeks during dose titration, then monthly once stable. Monitor for hypersensitivity reactions (e.g., anaphylaxis, injection site reactions). Fetal monitoring: ultrasound for growth and anatomy as per standard obstetrical care; consider fetal echocardiography if maternal phenylalanine levels are not well-controlled due to risk of congenital heart disease. |
| Fertility Effects | No dedicated fertility studies have been conducted. Animal studies did not show effects on male or female fertility at clinically relevant exposures. In women with phenylketonuria, improved metabolic control with PIZENSY may restore fertility by reducing ovulation disturbances associated with hyperphenylalaninemia. |